Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0050626 |
| Name | gastrointestinal neuroendocrine tumor |
| Definition | A gastrointestinal system cancer that has_material_basis_in neuroendocrine cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Xrefs |
|
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastrointestinal neuroendocrine tumor |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| NRAS Q61R | Trametinib | gastrointestinal neuroendocrine tumor | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02250885 | Phase II | Selinexor | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Completed | USA | 0 |
| NCT02315625 | Phase II | Everolimus Sunitinib | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | Terminated | USA | 0 |
| NCT02687958 | Phase II | Everolimus | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin | Unknown status | ITA | 0 |
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
| NCT02955069 | Phase II | Spartalizumab | Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 1 |
| NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
| NCT03043664 | Phase Ib/II | Lanreotide acetate + Pembrolizumab | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) | Completed | USA | 0 |
| NCT03049189 | Phase III | 177Lu-edotreotide Everolimus | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | 1 |
| NCT03095274 | Phase II | Durvalumab Tremelimumab | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) | Completed | ESP | 0 |
| NCT03278379 | Phase II | Avelumab | Avelumab in G2-3 NET (NET-002) | Completed | CAN | 0 |
| NCT03278405 | Phase Ib/II | Avelumab | Avelumab in G3 NEC (NET-001) | Completed | CAN | 0 |
| NCT03411915 | Phase I | XmAb18087 | A Study of XmAb18087 in Subjects With NET and GIST | Completed | USA | 0 |
| NCT03420521 | Phase II | Ipilimumab + Nivolumab | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | Terminated | USA | 0 |
| NCT03670030 | Phase II | Nab-rapamycin | A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System | Terminated | USA | 0 |
| NCT03870399 | Phase II | Tamoxifen | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET) | Completed | USA | BRA | 0 |
| NCT03879694 | Phase I | Octreotide + Sargramostim + SurVaxM | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | Completed | USA | 0 |
| NCT03891784 | Phase II | Abemaciclib | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
| NCT03901378 | Phase II | Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | Withdrawn | USA | 0 |
| NCT03972488 | Phase III | Octreotide acetate Lutetium Lu 177 dotatate + Octreotide acetate | Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
| NCT03980925 | Phase II | Carboplatin + Etoposide + Nivolumab | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. | Completed | ESP | 0 |
| NCT04086485 | Phase Ib/II | Lutetium Lu 177 dotatate + Olaparib | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | Recruiting | USA | 0 |
| NCT04400474 | Phase II | Atezolizumab + Cabozantinib | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) | Completed | ESP | 0 |
| NCT04427787 | Phase II | Cabozantinib + Lanreotide acetate | A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) | Unknown status | ITA | 0 |
| NCT04525638 | Phase II | Lutetium Lu 177 dotatate + Nivolumab | A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours | Unknown status | ESP | 0 |
| NCT04609592 | Phase I | Lutetium Lu 177 dotatate | Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | Recruiting | USA | 0 |
| NCT04893785 | Phase II | Cabozantinib + Temozolomide | A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM) | Recruiting | ITA | 0 |
| NCT04919226 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin 177Lu-edotreotide Everolimus Capecitabine + Temozolomide | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
| NCT05249114 | Phase I | Cabozantinib + Lutetium Lu 177 dotatate | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | Active, not recruiting | USA | 0 |
| NCT05262556 | Phase I | Ipilimumab + Nivolumab + Thymoquinone | TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas | Active, not recruiting | USA | 0 |
| NCT05364944 | Phase I | Debio 4126 + Lanreotide acetate Debio 4126 + Octreotide acetate | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01) | Terminated | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | 0 |
| NCT05475210 | Phase I | 177Lu-DOTA-EB-TATE | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | Recruiting | USA | 0 |
| NCT05477576 | Phase III | Everolimus Lanreotide acetate RYZ101 Sunitinib Octreotide acetate | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1) | Recruiting | USA | NLD | FRA | ESP | CAN | BRA | BEL | 1 |
| NCT05554003 | Phase II | Temozolomide | Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study (MeTe) | Recruiting | ITA | 0 |
| NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Active, not recruiting | USA | ITA | ISR | FRA | ESP | DEU | AUS | 3 |
| NCT05652686 | Phase I | PT217 | A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Recruiting | USA | 0 |
| NCT05701241 | FDA approved | Lanreotide acetate Octreotide acetate | Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA) | Recruiting | NLD | BEL | 0 |
| NCT05746208 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | Recruiting | USA | 0 |
| NCT05773274 | Phase II | Everolimus Lutetium Lu 177 dotatate | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial | Recruiting | USA | CAN | 0 |
| NCT05987176 | Phase II | Lutetium Lu 177 dotatate | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS) | Terminated | GBR | 0 |
| NCT05988918 | Phase II | CEP-11981 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | Recruiting | USA | 0 |
| NCT05997056 | Phase II | Nab-rapamycin | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Recruiting | USA | 0 |
| NCT06016855 | FDA approved | Lutetium Lu 177 dotatate | Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors | Recruiting | USA | 0 |
| NCT06055439 | Phase Ib/II | CHM-2101 CAR-T cells | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Recruiting | USA | 0 |
| NCT06202066 | Phase II | Montanide ISA 51 + Sargramostim + SurVaxM + Temozolomide | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | Recruiting | USA | 0 |
| NCT06395402 | Phase II | Lutetium Lu 177 dotatate | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID) | Recruiting | USA | 0 |
| NCT06427798 | Phase Ib/II | 212Pb-VMT-alpha-NET | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | Recruiting | USA | 0 |
| NCT06472388 | Phase II | Everolimus | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors (EVENET) | Recruiting | BRA | 0 |
| NCT06479811 | Phase I | 212Pb-VMT-alpha-NET | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | Recruiting | USA | 0 |
| NCT06788938 | Phase II | Tarlatamab | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | Recruiting | USA | 0 |
| NCT06790706 | Phase II | AB154 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (IMMUNORARE5) | Recruiting | FRA | 0 |
| NCT07006727 | Phase I | 225Ac-ETN029 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | Recruiting | USA | CAN | 1 |
| NCT07061080 | Phase II | Tarlatamab Fluorouracil + Irinotecan + Leucovorin + Tarlatamab | Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (RAGNAR) | Recruiting | FRA | ESP | 0 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | BEL | AUS | 0 |
| NCT07080242 | Phase I | BL-M14D1 | Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Recruiting | USA | 0 |
| NCT07150546 | Phase I | Lutetium Lu 177 dotatate | Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. | Recruiting | USA | 0 |
| NCT07278479 | Phase Ib/II | 212Pb-MP0712 | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | Recruiting | USA | 0 |
| NCT07337447 | Phase II | Fluorouracil + Irinotecan + Leucovorin AB154 + Fluorouracil + Irinotecan + Leucovorin + Zimberelimab | Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) (REWENEC 01) | Not yet recruiting | FRA | 0 |